Ryder, Mabel

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 570

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer

Cancer Immunotherapy and BiomarkersAdrenal Hormones and Disorders

Cited by 439

Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas

Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J. M., Knauf, J. A., Viale, A., Sherman, E. J., Ryder, M., Ghossein, R. A., Rosen, N., & Fagin, J. A. (2013) · Cancer Discovery

Melanoma and MAPK PathwaysThyroid Cancer Diagnosis and Treatment

Cited by 382

Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms

Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 278

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

Shonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., et al. (2022) · Head & Neck

Thyroid Cancer Diagnosis and TreatmentThyroid and Parathyroid Surgery

Cited by 117